Pharminent

Second US infliximab biosimilar launched at 35% discount to J&J’s Remicade

Merck & Co. will challenge both reference drugmaker J&J and fellow biosimilar developer Pfizer through its version of Remicade, Renflexis. http://www.biopharma-reporter.com/Markets-Regulations/Merck-Co.-launches-US-Remicade-biosimilar-at-35-discount

Filed under: Biosimilar